| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| ln Vitro |
Based on the Ki values of ETA (19 μM) and ETB (16 PM) receptors, IRL-1620 (TFA) is the most effective and specific ligand for the ETB receptor (KiETA/KiETB=120,000)[1]. IRL-1620 (TFA) is 60 times more selective for the ETB receptor than ET-3 (KiETA/KiETB=1,900)[1].
|
|---|---|
| ln Vivo |
IRL-1620 (TFA) (1-100 nM) can induce tracheal contraction in guinea pigs. The effective concentration of IRL-1620 that induces 30% contraction with 60 mM KCl is estimated to be 28 nM[1]. IRL-1620 (TFA) (1-100 nM) can increase the concentration of cytoplasmic Ca2+ ([Ca]E) in vascular endothelial cells, with little effect on resting muscle tone, and can relax the tension induced by norepinephrine stimulation in rat aorta, while increasing [Ca]E[1]. IRL-1620 (TFA) can improve learning and memory in water maze tasks and enhance angiogenesis and neurogenic remodeling. IRL-1620 treatment can significantly reduce Aβ-induced cognitive impairment. Compared with carrier treatment, IRL-1620 treatment can increase the number of VEGF-labeled vessels[2].
|
| References |
|
| Molecular Formula |
C88H118F3N17O29
|
|---|---|
| Molecular Weight |
1934.97
|
| Related CAS # |
IRL-1620
|
| Sequence |
{Suc}-Asp-Glu-Glu-Ala-Val-Tyr-Phe-Ala-His-Leu-Asp-Ile-Ile-Trp{Suc}-DEEAVYFAHLDIIW
|
| SequenceShortening |
{Suc}-DEEAVYFAHLDIIW
|
| Appearance |
White to off-white solid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封且受保护的环境中(例如氮气下),避免暴露在潮湿和光照下。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~25.84 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (1.29 mM) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Suspended solution; Need ultrasonic.
For example, if 1 mL of working solution is to be prepared, you canAdd 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of physiological saline: Dissolve 0.9 g of sodium chloride in double-distilled water and dilute to 100 mL to obtain clear physiological saline. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5168 mL | 2.5840 mL | 5.1680 mL | |
| 5 mM | 0.1034 mL | 0.5168 mL | 1.0336 mL | |
| 10 mM | 0.0517 mL | 0.2584 mL | 0.5168 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.